A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study.

Suzanne Meiring,Annieke C G van Baar, Nikolaj Sørensen,Frits Holleman,Maarten R Soeters,Max Nieuwdorp,Jacques J G H M Bergman

Frontiers in clinical diabetes and healthcare（2022）

引用 1|浏览3

暂无评分

摘要

The correlation between gut microbiota richness (alpha diversity) and HbA1c as well as the change in PDFF and changed microbiota composition (beta diversity) suggests that changed gut microbiota diversity is associated with metabolic improvements after DMR in combination with glucagon-like-peptide-1 receptor agonist in type 2 diabetes. Larger controlled studies are however needed to find causal links between DMR with GLP-1RA, the gut microbiota, and improvements in metabolic health.

查看译文

关键词

DMR,GLP-1RA,diabetes type 2,duodenal mucosal resurfacing,endoscopic,gut microbiota,microbiota diversity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要